Thyroid cancer

Cancer Letters

Volumn 163, Issue 2, 2001, Pages 143-156

  Gimm, Oliver ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Diagnosis; Follicular; Management; Medullary; p53; Papillary; PTEN; ras; RET; TRK; Undifferentiated

Indexed keywords

CISPLATIN; DOXORUBICIN; IODINE 131; OCTREOTIDE; PACLITAXEL; PROTEIN P53; RADIOACTIVE IODINE; RECOMBINANT ALPHA2B INTERFERON; VINCRISTINE;

ANAPLASTIC CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DIFFERENTIATION; EARLY DIAGNOSIS; FOLLICULAR CARCINOMA; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GERM LINE; HETEROZYGOSITY LOSS; HISTOLOGY; HUMAN; LYMPHADENECTOMY; MEDULLARY CARCINOMA; MISSENSE MUTATION; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; RADIATION; SHORT SURVEY; THYROID CARCINOMA; THYROIDECTOMY;

EID: 0035952364     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(00)00697-2     Document Type: Review

References (100)

1. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996
2. Patient care evaluation studies - A comprehensive concept for evaluation of oncologic patient management
3. Medullary (solid) carcinoma of the thyroid - A clinicopathologic entity
4. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma
5. Prevalence of sporadic medullary thyroid carcinoma: The importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules
6. Routine measurement of plasma calcitonin in nodular thyroid diseases
7. Prognostic factors in medullary thyroid carcinoma: Evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register
8. Multiple mucosal neuromas, pheochromocytoma, medullary carcinoma of the thyroid and marfanoid body build with muscle wasting: Reexamination of a syndrome of neural crest malmigration
9. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A
10. Familial adenomatous polyposis (Gardner's syndrome) and thyroid carcinoma. A case report and review of the literature
11. Cowden disease. A hereditary polyposis syndrome diagnosable by mucocutaneous inspection
12. Identification of FAP locus genes from chromosome 5q21
13. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients
14. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome
15. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer
16. A gene predisposing to familial thyroid tumors with cell oxyphilia maps to chromosome 19p13.2
17. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors
18. Somatic mutation of the APC gene in thyroid carcinoma associated with familial adenomatous polyposis
19. Evidence against involvement of APC mutation in papillary thyroid carcinoma
20. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors
21. Allelotyping of anaplastic thyroid carcinoma: Frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q
22. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas
23. A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma
24. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma
25. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer
26. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5
27. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary thyroid carcinomas
28. Translocation t(10;14) (q11.2:q22.1) fusing the kinetin to the RET gene creates a novel rearranged form (PTC8) of the RET proto-oncogene in radiation-induced childhood papillary thyroid carcinoma
29. Fusion of a novel gene, ELKS, to RET due to translocation t(10;12)(q11;p13) in a papillary thyroid carcinoma
30. RET/PCM-1: A novel fusion gene in papillary thyroid carcinoma
31. In vitro irradiation is able to cause RET oncogene rearrangement
32. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells
33. Epidemiologic and clinical evaluation of thyroid cancer in children from the Gomel region (Belarus)
34. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation
35. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children
36. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus
37. Cytogenetic and molecular genetic characterization of papillary thyroid carcinomas
38. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas
39. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain
40. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma
41. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas
42. Genetic alterations in thyroid tumor progression: Association with p53 gene mutations
43. Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma
44. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland
45. The highly malignant phenotype of anaplastic thyroid carcinoma cell lines is recessive
46. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis
47. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation
48. C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B
49. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease
50. Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2
51. Natural history, treatment, and course of papillary thyroid carcinoma
52. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: A matched-pair analysis
53. Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow-up
54. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system
55. Papillary thyroid carcinoma: The new, age-related TNM classification system in a retrospective analysis of 199 patients
56. Papillary carcinoma of the thyroid
57. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid cancer
58. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989
59. Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma
60. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables
61. Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients
62. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma
63. Expanding role of fine-needle aspiration cytology in thyroid diagnosis and management
64. Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes
65. Serum thyroglobulin measurements in differentiated thyroid cancer
66. Germline V804M mutation in th RET proto-oncogene in two apparently sporadic cases of TMC presenting in the seventh decade of life
67. Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG->ATG) mutation
68. Preoperative diagnosis of medullary thyroid carcinoma by RT-PCR using RNA extracted from leftover cells within a needle used for fine needle aspiration biopsy
69. Ultrasound-guided fine-needle aspiration biopsy of the thyroid: Role of on-site assessment and multiple cytologic preparations
70. Ultrasound of the thyroid and parathyroid glands
71. Lymph node metastases: CT and MRI
72. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996
73. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer
74. Origin and progression of thyroid epithelial tumours: Cellular and molecular mechanisms
75. Late cervical lymph node recurrence in differentiated thyroid carcinoma. An inherent problem of 131I beta dose distribution in small tumor deposits?
76. Anaplastic thyroid carcinoma: A therapeutic challenge
77. Improved prediction of calcitonin normalization in medullary thyroid carcinoma patients by quantitative lymph node analysis
78. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma
79. Risk estimation and screening in families of patients with medullary thyroid carcinoma
80. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A
81. Prophylactic thyroidectomy in 75 children and adolescents with hereditary medullary thyroid carcinoma: German and Austrian experience
82. Is thyroidectomy necessary in RET mutations carriers of the familial medullary thyroid carcinoma syndrome?
83. Redifferentiation therapy with retinoids: Therapeutic option for advanced follicular and papillary thyroid carcinoma
84. Innovative strategies for the treatment of thyroid cancer
85. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4)
86. Phase II evaluation of high dose accelerated radiotherapy for anaplastic thyroid carcinoma
87. Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols
88. Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion
89. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells
90. Effects of exogenous p53 transduction in thyroid tumor cells with different p53 status
91. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line
92. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies
93. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: Doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type
94. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide
95. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide
96. High level, tissue-specific expression of a modified calcitonin/calcitonin gene-related peptide promoter in a human medullary thyroid carcinoma cell line
97. Genetic immunotherapy for medullary thyroid carcinoma: Destruction of tumors in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene
98. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: Relationship of bystander effect and antitumor efficacy
99. Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications